Review article · 2025 · Open access

Engineering Lipid Nanoparticles for mRNA Immunotherapy

Robby C. Zwolsman, Youssef Bahaaeldin Darwish, Ewelina Kluza, Roy van der Meel

Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, 17(2), e70007 · Published 1 March 2025 · DOI 10.1002/wnan.70007

Open full textCite this paper

In brief

“Engineering Lipid Nanoparticles for mRNA Immunotherapy” is a 2025 review article by Robby C. Zwolsman and 3 co-authors, published in Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology. OpenAlex counts 43 citations as of 21 November 2026, which puts it in the top 1% of works published in 2025 by citations. It is open access under a CC BY-NC licence: the full text is free to read at Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology.

Citations
43
Most cited in
2026 (31)
Field-weighted impact
2.69
References
210
Authors
4

Abstract

Over the last decades, messenger RNA (mRNA) has emerged as a promising therapeutic modality, enabling the delivery of genetic instructions to cells for producing therapeutic proteins or antigens. As such, mRNA-based therapies can be developed for a wide range of conditions, including infections, cancer, metabolic disorders, and genetic diseases. Nevertheless, using mRNA therapeutically requires chemical modifications to reduce immunostimulatory effects and nanotechnology to prevent degradation and ensure intracellular delivery. Lipid nanoparticles (LNPs) have become the most effective delivery platform for mRNA therapeutics, which are primarily employed for vaccine purposes following local administration and hepatic applications following systemic administration. Here, we review the state-of-the-art LNP-mRNA technology and discuss its potential for immunotherapy. We first outline the requirements for mRNA to be used therapeutically, including the role of LNP-mediated delivery. Next, we highlight LNP-mRNA immunotherapy approaches for vaccination, immuno-oncology, and autoimmune disorders. In addition, we discuss challenges that are limiting LNP-mRNA's widespread use, including tunable biodistribution and immunostimulatory effects. Finally, we provide an outlook on how implementing approaches such as library screening and machine learning will guide the development of next-generation mRNA therapeutics.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Zwolsman, R. C., Darwish, Y. B., Kluza, E., & van der Meel, R. (2025). Engineering Lipid Nanoparticles for mRNA Immunotherapy. Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, 17(2), e70007. https://doi.org/10.1002/wnan.70007

MLA 9

Zwolsman, Robby C., et al. “Engineering Lipid Nanoparticles for mRNA Immunotherapy.” Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, vol. 17, no. 2, 2025, p. e70007. https://doi.org/10.1002/wnan.70007.

Chicago

Zwolsman, Robby C., Youssef Bahaaeldin Darwish, Ewelina Kluza, and Roy van der Meel. 2025. “Engineering Lipid Nanoparticles for mRNA Immunotherapy.” Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology 17 (2): e70007. https://doi.org/10.1002/wnan.70007.

Harvard

Zwolsman, R. C. et al. (2025) ‘Engineering Lipid Nanoparticles for mRNA Immunotherapy’, Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, 17(2), p. e70007. doi:10.1002/wnan.70007.

IEEE

R. C. Zwolsman, Y. B. Darwish, E. Kluza, and R. van der Meel, “Engineering Lipid Nanoparticles for mRNA Immunotherapy,” Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, vol. 17, no. 2, p. e70007, 2025, doi: 10.1002/wnan.70007.

BibTeX

@article{zwolsman2025engineering,
  title     = {{Engineering Lipid Nanoparticles for mRNA Immunotherapy}},
  author    = {Zwolsman, Robby C. and Darwish, Youssef Bahaaeldin and Kluza, Ewelina and van der Meel, Roy},
  journal   = {Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology},
  year      = {2025},
  volume    = {17},
  number    = {2},
  pages     = {e70007},
  doi       = {10.1002/wnan.70007},
  url       = {https://doi.org/10.1002/wnan.70007}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery

  • lipid nanoparticles
  • mRNA therapeutics
  • mRNA delivery
  • mRNA vaccines
  • cancer immunotherapy
  • autoimmune disease
  • immunostimulatory effects
  • tissue distribution

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Zwolsman, R. C., Darwish, Y. B., Kluza, E., & van der Meel, R. (2025). Engineering Lipid Nanoparticles for mRNA Immunotherapy. Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, 17(2), e70007. https://doi.org/10.1002/wnan.70007

How many times has this paper been cited?

43 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology: sign in and open the full text from this page.

Who wrote this paper?

Robby C. Zwolsman, Youssef Bahaaeldin Darwish, Ewelina Kluza, Roy van der Meel.

What is the DOI of this paper?

10.1002/wnan.70007, permanently at https://doi.org/10.1002/wnan.70007. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.